CytomX Therapeutics (CTMX) Net Margin (2014 - 2026)
CytomX Therapeutics posted quarterly Net Margin of 177.89% for Q1 2026, down 22409.0% year-on-year from N/an in Q1 2025, and up 95.55% on a QoQ basis from 3998.49% in Q4 2025.
CytomX Therapeutics (CTMX) has 13 years of Net Margin data on file, last reported at 177.89% in Q1 2026.
- For the quarter ending Q1 2026, Net Margin fell 22409.0% year-over-year to 177.89%; the trailing twelve-month figure through Mar 2026 stood at 166.4% (down 19459.0% YoY), and the FY2025 full-year result was 26.73%, down 4981.0% from the prior year.
- Net Margin for Q1 2026 stood at 177.89%, up from 3998.49% in the prior quarter.
- Across five years, Net Margin topped out at 49.55% in Q4 2024 and bottomed at 3998.49% in Q4 2025.
- The 5-year median for Net Margin is 14.09% (2023), against an average of 305.13%.
- The widest annual swing landed in 2023, when Net Margin jumped 33968 bps; it then slumped 404804 bps in 2025.
- A 5-year view of Net Margin shows it stood at 43.61% in 2022, then soared by 107 bps to 3.15% in 2023, then jumped by 1475 bps to 49.55% in 2024, then tumbled by 8169 bps to 3998.49% in 2025, then jumped by 96 bps to 177.89% in 2026.
- The last three Net Margin figures came in at 177.89% (Q1 2026), 3998.49% (Q4 2025), and 238.62% (Q3 2025), per Business Quant data.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Net Margin (Qtr) |
|---|---|---|---|---|---|
| 1 | Quantum Biopharma | 1,216,509.61 Bn | 1,216,509.61 Bn | - | - |
| 2 | Alterity Therapeutics | 764,224.41 Bn | 764,224.38 Bn | - | - |
| 3 | Legend Biotech | 2,716.00 Bn | 2,715.71 Bn | 242.10 Mn | 0.82% |
| 4 | Nanobiotix | 2,248.83 Bn | 2,248.77 Bn | - | - |
| 5 | Akari Therapeutics | 1,951.18 Bn | 1,951.17 Bn | - | - |
| 6 | Vertex Pharmaceuticals | 113.69 Bn | 106.44 Bn | 2.59 Bn | 34.53% |
| 7 | Evaxion A | 64.16 Bn | 64.14 Bn | - | - |
| 8 | Regeneron Pharmaceuticals | 63.94 Bn | 55.18 Bn | 3.31 Bn | 20.17% |
| 9 | Alnylam Pharmaceuticals | 40.13 Bn | 37.12 Bn | 959.66 Mn | 17.65% |
| 10 | CytomX Therapeutics | 638.18 Mn | 291.48 Mn | - | -177.89% |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -177.89% |
| Dec 31, 2025 | -3,998.49% |
| Sep 30, 2025 | -238.62% |
| Jun 30, 2025 | -0.83% |
| Mar 31, 2025 | 46.20% |
| Dec 31, 2024 | 49.55% |
| Sep 30, 2024 | 17.16% |
| Jun 30, 2024 | -26.02% |
| Mar 31, 2024 | 33.26% |
| Dec 31, 2023 | 3.15% |
| Sep 30, 2023 | 11.34% |
| Jun 30, 2023 | -4.40% |
| Mar 31, 2023 | -14.09% |
| Dec 31, 2022 | -43.61% |
| Sep 30, 2022 | -260.73% |
| Jun 30, 2022 | -229.49% |
| Mar 31, 2022 | -353.77% |
| Dec 31, 2021 | -312.82% |
| Sep 30, 2021 | -337.16% |
| Jun 30, 2021 | -303.99% |
| Mar 31, 2021 | -284.59% |
| Dec 31, 2020 | -339.02% |
| Sep 30, 2020 | -335.28% |
| Jun 30, 2020 | -362.03% |
| Mar 31, 2020 | 35.74% |
| Dec 31, 2019 | -798.16% |
| Sep 30, 2019 | -221.24% |
| Jun 30, 2019 | -321.31% |
| Mar 31, 2019 | -81.17% |
| Dec 31, 2018 | -281.00% |
| Sep 30, 2018 | -187.30% |
| Jun 30, 2018 | -135.92% |
| Mar 31, 2018 | -109.23% |
| Dec 31, 2017 | 0.40% |
| Sep 30, 2017 | -42.44% |
| Jun 30, 2017 | -288.12% |
| Mar 31, 2017 | -70.86% |
| Dec 31, 2016 | -223.74% |
| Sep 30, 2016 | -424.49% |
| Jun 30, 2016 | -458.18% |
| Mar 31, 2016 | -721.05% |
| Dec 31, 2015 | -605.89% |
| Sep 30, 2015 | -764.72% |
| Jun 30, 2015 | -370.19% |
| Mar 31, 2015 | -438.75% |
| Dec 31, 2014 | -321.49% |
| Sep 30, 2014 | -248.46% |